ResMed Q4 Beat Masks Core Question: Can FY27 Guidance Sustain the Recovery?

What happened

ResMed’s Q4 FY2026 earnings of $2.95 per share exceeded the $2.90 Zacks consensus, marking a 15% increase from the prior year’s $2.55. The beat came as the company closed a fiscal year marked by double-digit revenue growth, expanding gross margins, and a 20%-plus free-cash-flow surge to over $520 million per quarter. However, the headline beat does little to settle the two overhangs that have driven the stock 39% below its July 2025 highs: the structural risk of GLP-1 drugs reducing PAP demand and Philips’ eventual U.S. re-entry. The DeepValue report had rated RMD a POTENTIAL BUY at $202.8 but explicitly tied its conviction to the August 6 FY2027 guidance, requiring core revenue growth above 8% and gross margin above 62%. With the Q4 print already in the rearview mirror, the real test is whether management’s outlook confirms resilient unit-led demand and stable installed-base economics or reveals early signs of competitive and therapeutic pressure.

Implication

The Q4 beat is incrementally positive, but the margin of safety remains tied to guidance. If the FY2027 outlook holds core Sleep & Breathing Health growth above 8% and gross margins above 62%, the stock has room to rerate toward the mid-$220s, as the bear case of imminent GLP-1 erosion or Philips disruption remains unsupported by current data. Conversely, any hint of slowing device growth, rising discounts, or a margin guide below 62% would break the thesis and likely send shares back toward $175. The MatrixCare sale and $500 million in buybacks provide EPS support, but these are financial tailwinds, not operational ones; the operating story must stand on its own. For now, the stock remains a show-me story, and the August 6 call is the pivotal event.

Thesis delta

The Q4 beat aligns with the base case that demand remains healthy, but it does not address the key overhangs. The thesis remains cautious: guidance is the gating factor, and without assurance that GLP-1s and Philips are not eroding the funnel, the stock’s rerating potential stays capped. No change to the POTENTIAL BUY rating pending the outlook.